Skip to content

Study · Randomized controlled trial · n = 15 · 2000

6 results

Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy).

Tahara M, Matsuoka T, Yokoi T, Tasaka K, Kurachi H, Murata Y

Fertility and sterility1 Apr 2000Cited by 19 (Europe PMC)

PMID10731543 (opens in a new tab)DOI10.1016/s0015-0282(99)00636-6 (opens in a new tab)PepBankPUB-10731543
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In symptomatic endometriosis, subjective manifestations decreased similarly with decreasing-dose and full-dose nafarelin.

    In plain wordsSubjective endometriosis symptoms improved similarly with decreasing-dose and full-dose nafarelin.

    Peptide
    Nafarelin
    Outcome
    Direction not reportedSubjective endometriosis manifestations
    Study

    n = 15

    Comparator
    Full-dose nafarelin 200 microgram twice daily for 24 weeks
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    200 microgram twice daily for 4 weeks, then 200 microgram daily for 20 weeks · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Subjective and objective manifestations of endometriosis were decreased to a similar extent in both study groups.
    2 context sentences
    Summary · context
    Patients with symptomatic endometriosis.
    Summary · context
    Fifteen patients were randomized to receive either full-dose nafarelin treatment (200 microgram b.i.d.) for 24 weeks (n = 7) or full-dose nafarelin treatment for 4 weeks followed by half-dose nafarelin treatment (200 microgram daily) for 20 weeks (n = 8).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In symptomatic endometriosis, objective manifestations decreased similarly with decreasing-dose and full-dose nafarelin.

    In plain wordsObjective endometriosis signs improved similarly with decreasing-dose and full-dose nafarelin.

    Peptide
    Nafarelin
    Outcome
    Direction not reportedObjective endometriosis manifestations
    Study

    n = 15

    Comparator
    Full-dose nafarelin 200 microgram twice daily for 24 weeks
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    200 microgram twice daily for 4 weeks, then 200 microgram daily for 20 weeks · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Subjective and objective manifestations of endometriosis were decreased to a similar extent in both study groups.
    2 context sentences
    Summary · context
    Patients with symptomatic endometriosis.
    Summary · context
    Fifteen patients were randomized to receive either full-dose nafarelin treatment (200 microgram b.i.d.) for 24 weeks (n = 7) or full-dose nafarelin treatment for 4 weeks followed by half-dose nafarelin treatment (200 microgram daily) for 20 weeks (n = 8).
  3. 03HumanRandomized controlled trialSafety outcome

    In symptomatic endometriosis, adverse effects were markedly reduced with decreasing-dose nafarelin versus full-dose treatment.

    In plain wordsDecreasing-dose nafarelin produced fewer adverse effects than full-dose treatment.

    Peptide
    Nafarelin
    Outcome
    DecreaseAdverse effects
    Study

    n = 15

    Comparator
    Full-dose nafarelin 200 microgram twice daily for 24 weeks
    Outcome group
    Adverse events · Whole body
    Studied dose
    200 microgram twice daily for 4 weeks, then 200 microgram daily for 20 weeks · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Adverse effects were markedly reduced with half-dose administration.
    2 context sentences
    Summary · context
    Patients with symptomatic endometriosis.
    Summary · context
    Fifteen patients were randomized to receive either full-dose nafarelin treatment (200 microgram b.i.d.) for 24 weeks (n = 7) or full-dose nafarelin treatment for 4 weeks followed by half-dose nafarelin treatment (200 microgram daily) for 20 weeks (n = 8).
  4. 04HumanRandomized controlled trialSafety outcome

    In symptomatic endometriosis, bone mineral density loss was significantly less with decreasing-dose nafarelin than full-dose treatment.

    In plain wordsDecreasing-dose nafarelin caused less bone density loss than full-dose treatment.

    Peptide
    Nafarelin
    Outcome
    DecreaseBone mineral density loss
    Study

    n = 15

    Comparator
    Full-dose nafarelin 200 microgram twice daily for 24 weeks
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 microgram twice daily for 4 weeks, then 200 microgram daily for 20 weeks · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Loss of bone mineral density was significantly less with half-dose treatment.
    2 context sentences
    Summary · context
    Patients with symptomatic endometriosis.
    Summary · context
    Fifteen patients were randomized to receive either full-dose nafarelin treatment (200 microgram b.i.d.) for 24 weeks (n = 7) or full-dose nafarelin treatment for 4 weeks followed by half-dose nafarelin treatment (200 microgram daily) for 20 weeks (n = 8).
  5. 05HumanNon-randomized trialEfficacy outcome

    In the decreasing-dose endometriosis group, serum estradiol was significantly suppressed after 4 weeks of full-dose nafarelin.

    In plain wordsEstradiol decreased after four weeks of full-dose nafarelin in the decreasing-dose group.

    Peptide
    Nafarelin
    Outcome
    DecreaseEstradiol suppression at four weeks
    Study

    n = 8

    Comparator
    Before treatment
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    200 microgram twice daily · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    In the half-dose group, the mean serum E(2) level was significantly suppressed by 4 weeks of treatment with full-dose nafarelin and remained at approximately 30 pg/mL with half-dose nafarelin.
    2 context sentences
    Summary · context
    Patients with symptomatic endometriosis.
    Summary · context
    Fifteen patients were randomized to receive either full-dose nafarelin treatment (200 microgram b.i.d.) for 24 weeks (n = 7) or full-dose nafarelin treatment for 4 weeks followed by half-dose nafarelin treatment (200 microgram daily) for 20 weeks (n = 8).
  6. 06HumanNon-randomized trialEfficacy outcome

    In the decreasing-dose endometriosis group, serum estradiol remained at approximately 30 pg/mL during half-dose nafarelin.

    In plain wordsEstradiol remained near 30 pg/mL during half-dose nafarelin in women with endometriosis.

    Peptide
    Nafarelin
    Outcome
    Not applicableEstradiol during half-dose treatment
    Study

    n = 8

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    200 microgram daily · 20 weeksAs given in this study (human).

    Measurements

    Serum E2
    ≈ 30 pg/mL
    half-dose nafarelin, half-dose group

    Source sentences

    Summary
    In the half-dose group, the mean serum E(2) level was significantly suppressed by 4 weeks of treatment with full-dose nafarelin and remained at approximately 30 pg/mL with half-dose nafarelin.
    2 context sentences
    Summary · context
    Patients with symptomatic endometriosis.
    Summary · context
    Fifteen patients were randomized to receive either full-dose nafarelin treatment (200 microgram b.i.d.) for 24 weeks (n = 7) or full-dose nafarelin treatment for 4 weeks followed by half-dose nafarelin treatment (200 microgram daily) for 20 weeks (n = 8).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.